Vor Biopharma (VOR) Form 3: Director Reports 0 Shares

Vor Biopharma Inc. (VOR) filing an initial Form 3 by reporting person Sarah Burgess Reed shows she is identified as a director and that, as of the event date 08/27/2025, no securities are beneficially owned by her.

Rhea-AI Filing Summary

Vor Biopharma Inc. (VOR) filing an initial Form 3 by reporting person Sarah Burgess Reed shows she is identified as a director and that, as of the event date 08/27/2025, no securities are beneficially owned by her. The filing is marked as an initial statement and was signed on 09/08/2025 by an attorney-in-fact, Sherell Bacchas.

This is a routine Section 16 disclosure showing the reporting relationship and a declaration of zero ownership of the issuer's equity. The form does not report any derivative holdings, purchases, sales, or other transactions and contains no financial tables or material transaction details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Vor Biopharma's (VOR) Form 3 filed by Sarah Burgess Reed report?

The Form 3 identifies Sarah Burgess Reed as a director and states she beneficially owns no securities of Vor Biopharma as of 08/27/2025.

Does the Form 3 show any stock purchases or options by the director?

No. The filing explicitly states no securities are beneficially owned and lists no non-derivative or derivative holdings.

When was the Form 3 signed and by whom?

The signature block shows the form was signed on 09/08/2025 by Sherell Bacchas, acting as attorney-in-fact for the reporting person.

Is this filing an initial disclosure or an amendment?

This is an initial Form 3 filing; the form indicates it was filed by one reporting person and not marked as an amendment.

Does the Form 3 disclose any derivative securities or expiration/exercise details?

No. The derivative securities table contains no entries; there are no exercisable dates, exercise prices, or underlying share amounts reported.

Does the Form 3 reveal any material transactions affecting investors?

No. The document contains no purchases, sales, grants, or other transactions and therefore shows no material investor-impacting events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/08/2025 - 09:19 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reed Sarah Burgess

(Last) (First) (Middle)

C/O VOR BIOPHARMA INC.

500 BOYLSTON STREET, SUITE 1350

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/27/2025

3. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Sherell Bacchas, Attorney-in-Fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.